1. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (2020 report). 2019. [
URL]
2. Rezaeetalab F, Hamidi alamdari D, Dalili A. Oxidative stress in COPD, pathogenesis and therapeutic views. Rev Clin Med 2014;1(3):115-24. [
Google Scholar]
3. Duarte-de-Araújo A, Teixeira P, Hespanhol V, Correia-de-Sousa J. Characterisation of morbidity in a COPD hospital cohort. Pulmonology 2019; 25(4):200-7. [
DOI:10.1016/j.pulmoe.2019.02.010] [
PMID]
4. Ko FW, Chan KP, Hui DS, Goddard JR, Shaw JG, Reid DW, et al. Acute exacerbation of COPD. Respirology 2016;21(7):1152-65. [
DOI:10.1111/resp.12780] [
PMID] [
PMCID]
5. Hillas G, Perlikos F, Tzanakis N. Acute exacerbation of COPD: is it the "stroke of the lungs"? Int J Chron Obstruct Pulmon Dis 2016;11:1579-86. [
DOI:10.2147/COPD.S106160] [
PMID] [
PMCID]
6. Adibi A, Sin DD, Safari A, Johnson KM, Aaron SD, FitzGerald JM, et al. The Acute COPD Exacerbation Prediction Tool (ACCEPT): a modelling study. Lancet Respir Med 2020;8(10):1013-21. [
DOI:10.1016/S2213-2600(19)30397-2] [
PMID]
7. Kim V, Aaron S D. What is a COPD exacerbation? Current definitions, pitfalls, challenges and opportunities for improvement. Eur Respir J 2018;52(5):1801261. [
DOI:10.1183/13993003.01261-2018] [
PMID]
8. Sharifi H, Masjedi MR, Emami H, Ghanei M, Eslaminejad A, Radmand G, et. al. Burden of obstructive lung disease study in Tehran: Prevalence and risk factors of chronic obstructive pulmonary disease. Lung India 2015;32(6):572. [
DOI:10.4103/0970-2113.168129] [
PMID] [
PMCID]
9. Balter MS, La Forge J, Low DE, Mandell L, Grossman RF. Chronic Bronchitis Working Group. Canadian guidelines for the management of acute exacerbations of chronic bronchitis. Can Respir J 2003;10(Suppl B):3B-2B. [
DOI:10.1155/2003/486285] [
PMID]
10. Anthonisen NR, Manfreda J, Warren CP, Hershfield ES, Harding GK, Nelson NA. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 1987;106(2):196-204. [
DOI:10.7326/0003-4819-106-2-196] [
PMID]
11. Şahin F, Koşar AF, Aslan AF, et al. Serum Biomarkers in Patients with Stable and Acute Exacerbation of Chronic Obstructive Pulmonary Disease: A Comparative Study. J Med Biochem 2019;38:503-11. [
DOI:10.2478/jomb-2018-0050] [
PMID] [
PMCID]
12. Boersma WG. Antibiotics in acute exacerbations of COPD: the good, the bad and the ugly. Eur Respir J 2012;40(1):1-3. [
DOI:10.1183/09031936.00211911] [
PMID]
13. El Halim AA, Sayed M. The value of serum procalcitonin among exacerbated COPD patients. Egypt J Chest Dis Tuberc 2015;64(4):821-7. [
DOI:10.1016/j.ejcdt.2015.05.016]
14. Charles P, Ladoire S, Aho S, Quenot P, Doise JM, Prin S. Serum procalcitonin elevation in critically ill patients at the onset of bacteremia caused by either gram negative or gram-positive bacteria. BMC Infect Dis 2008;8(1):1-8. [
DOI:10.1186/1471-2334-8-38] [
PMID] [
PMCID]
15. Choi JJ, McCarthy MW. Novel applications for serum procalcitonin testing in clinical practice. Expert Rev Mol Diagn 2018;18(1):27-34. [
DOI:10.1080/14737159.2018.1407244] [
PMID]
16. Davies J. Procalcitonin. J Clin Pathol 2015;68(9):675-9. [
DOI:10.1136/jclinpath-2014-202807] [
PMID]
17. Bafadhel M, Clark TW, Reid C, Medina M-j, Batham S, Barer MR, et al. Procalcitonin and c-reactive protein in hospitalized adult patients with community-acquired pneumonia or exacerbation of asthma or COPD. Chest 2011;139(6):1410-8. [
DOI:10.1378/chest.10-1747] [
PMID] [
PMCID]
18. Stolz D, Christ-Crain M, Bingisser R, Leuppi J, Miedinger D, Müller C, et al. Antibiotic treatment of exacerbations of COPD: a randomized, controlled trial comparing procalcitonin-guidance with standard therapy. Chest 2007;131. [
DOI:10.1378/chest.06-1500] [
PMID]
19. Delghandi M, Rezaeetalab F, Ebrahimzadeh F, Najaf Najafi M. Investigation serum procalcitonin in patients with exacerbation of obstructive pulmonary disease. J Cardiothorac Med 2020;8(4):700-6. [
Google Scholar]
20. Mohamed KH, Abderabo MM, Ramadan ES. Hashim MM, Sharaf SM. Procalcitonin as a diagnostic marker in acute exacerbation of COPD. Egypt J Chest Dis Tuberc 2012;61(4):301-5. [
DOI:10.1016/j.ejcdt.2012.08.011]
21. Li Y, Xie L, Xin S, Li K. Values of procalcitonin and C-reactive proteins in the diagnosis and treatment of chronic obstructive pulmonary disease having concomitant bacterial infection. Pak J Med Sci 2017;33(3):566. [
DOI:10.12669/pjms.333.12554] [
PMID] [
PMCID]
22. Ergan B, Şahin AA, Topeli A. Serum procalcitonin as a biomarker for the prediction of bacterial exacerbation and mortality in severe COPD exacerbations requiring mechanical ventilation. Respiration 2016;91(4):316-24. [
DOI:10.1159/000445440] [
PMID]
23. Li Y, Xie L, Xin S, Li K. Values of procalcitonin and C-reactive proteins in the diagnosis and treatment of chronic obstructive pulmonary disease having concomitant bacterial infection. Pak J Med Sci 2017;33(3):566. [
] [
PMID] [
PMCID]
24. Ni W, Bao J, Yang D, Xi W, Wang K, Xu Y, Zhang R, Gao Z. Potential of serum procalcitonin in predicting bacterial exacerbation and guiding antibiotic administration in severe COPD exacerbations: a systematic review and meta-analysis. Infect Dis 2019;51(9):639-50. [
] [
PMID]
25. Meng FS, Su L, Tang YQ, Wen Q, Liu YS, Liu ZF. Serum Procalcitonin at the Time of Admission to the ICU as a Predictor of Short-Term Mortality. Clin Biochem 2009;42(10):1025-31. [
DOI:10.1016/j.clinbiochem.2009.03.012] [
PMID]
26. Ergan B, Şahin AA, Topeli A. Serum procalcitonin as a biomarker for the prediction of bacterial exacerbation and mortality in severe COPD exacerbations requiring mechanical ventilation. Respiration 2016;91:316-24. [
] [
PMID]